• Explore /
  • Poster
  • / A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer.

A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer.

Abstract Poster

Authors

null

Denise A. Yardley

Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

Denise A. Yardley , Ahmad Awada , Javier Cortes , Howard A. Burris III, Amy C. Peterson , Iulia Cristina Tudor , Shanna Stopatschinskaja , Joyce Leta Steinberg , Luca Gianni , Kathy D. Miller , Eric P. Winer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

ER+

Clinical Trial Registration Number

NCT02007512

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS653)

DOI

10.1200/jco.2014.32.15_suppl.tps653

Abstract #

TPS653

Poster Bd #

116B

Abstract Disclosures

Similar Posters

First Author: A. Dimitrios Dimitrios Colevas

First Author: Sukeshi Patel Arora

First Author: Matthew Raymond Smith

First Author: Johann S. De Bono